Intradermal recombinant human nerve growth factor induces pressure allodynia and lowered heat-pain threshold in humans

Neurology

Volumn 48, Issue 2, 1997, Pages 501-505

  Dyck, P J ^a,b   Peroutka, S ^c   Rask, C ^d   Burton, E ^d   Baker, M K ^a   Lehman, K A ^a   Gillen, D A ^a   Hokanson, J L ^a   O'Brien, P C ^b  

^a Peripheral Neuropathy Research Center   (United States)

^b MAYO CLINIC   (United States)

^c Spectra Biomedical Inc   (United States)

^d GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT NERVE GROWTH FACTOR; SODIUM CHLORIDE;

ADULT; AGED; ALLODYNIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HEATING; HUMAN; HUMAN EXPERIMENT; HYPERALGESIA; INJECTION SITE; INTRADERMAL DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PAIN THRESHOLD; PRESSURE SENSE; PRIORITY JOURNAL; TACTILE STIMULATION;

EID: 0031020724     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.48.2.501     Document Type: Article

References (20)

1. Levi-Montalcini R. The nerve growth factor thirty-five years later. Biosci Rep 1987;7:681-699.
2. Apfel SC, Lipton RB, Arezzo JC, Kessler JA. Nerve growth factor prevents toxic neuropathy in mice. Ann Neurol 1991;29: 87-90.
3. Apfel SC, Arezzo JC, Lipson L, Kessler JA. Nerve growth factor prevents experimental cisplatin neuropathy. Ann Neurol 1992;31:76-80.
4. Apfel SC, Arezzo JC, Brownlee M, Federoff H, Kessler JA. Nerve growth factor administration protects against experimental diabetic sensory neuropathy. Brain Res 1994;634:7-12.
5. Petty BG, Cornblath DR, Adornato BT, et al. The effect of systemically administered recombinant human nerve growth factor in healthy human subjects. Ann Neurol 1994;36:244-246.
6. Dyck PJ. Quantitating severity of neuropathy. In: Dyck PJ, Thomas PK, Griffin JW, Low PA, Poduslo JF, eds. Peripheral neuropathy. 3rd ed. Philadelphia: W.B. Saunders, 1993;686-697.
7. Dyck PJ, Zimmerman IR, Johnson DM, et al. A standard test of heat-pain (HPVAS) using CASE IV. J Neurol Sci 1996;136: 31-36.
8. Gorin PD, Johnson EM. Experimental autoimmune model of nerve growth factor deprivation: effects on developing peripheral sympathetic and sensory neurons. Proc Natl Acad Sci USA 1979;76:5382-5386.
9. Greene LA, Shooter EM. The nerve growth factor: biochemistry, synthesis and mechanism of action. Annu Rev Neurosci 1980;3:353-402.
10. Korsching S, Auberger G, Heumann R. Levels of nerve growth factor and its mRNA in the central nervous system of therate correlate with cholinergic innervation. EMBO J 1985;4:1389-1393.
11. Thoenen H, Barde YA. Physiology of nerve growth factor. Physiol Rev 1980;60:1284-1335.
12. Goedert M, Stoeckel K, Otten U. Biological importance of the retrograde axonal transport of nerve growth factor in sensory neurons. Proc Natl Acad Sci USA 1981;78:5895-5898.
13. Ochs S, Brimijoin WS. Axonal transport. In: Dyck PJ, Thomas PK, Griffin JW, Low PA, Poduslo JF, eds. Peripheral neuropathy. 3rd ed. Philadelphia: W.B. Saunders, 1993:331-360.
14. Lewin GR, Mendell LM. Nerve growth factor and nociception. Trends Neurosci 1993;16:353-359.
15. Levine JD, Taiwo YO, Collins SD, Tam JK. Noradrenaline hyperalgesia is mediated through interaction with sympathetic postganglionic neurone terminals rather than activation of primary afferent nociceptors. Nature 1986;323:158-160.
16. Bischoff SC, Dahinden CA. Effect of nerve growth factor on the release of inflammatory mediators by mature human basophils. Blood 1992;79:2662-2669.
17. Taiwo YO, Levine JD, Burch RM, Woo JE, Mobley WC. Hyperalgesia induced in the rat by the amino-terminal octapeptide of nerve growth factor. Proc Natl Acad Sci USA 1991;88: 5144-5148.
18. De Simone R, Alleva E, Tirassa P, Aloe L. Nerve growth factor released into the bloodstream following intraspecific fighting induces mast cell degranulation in adult male mice. Brain Behav Immun 1990;4:74-81.
19. Tomioka M, Stead RH, Nielsen L, Coughlin MD, Bienenstock J. Nerve growth factor enhances antigen and other secretagogue-induced histamine release from rat peritoneal mast cells in the absence of phosphatidylserine. J Allergy Clin Immunol 1988;82:599-607.
20. Dyck PJ. Diabetic polyneuropathy in controlled clinical trials: consensus report of the Peripheral Nerve Society. Ann Neurol 1995:38:478-482.